IFC may invest upto $25Mn in Super Religare Laboratories. The fund will be used to repay debt and also support its expansion plans of opening new laboratories across India and, potentially, across several lower middle-income countries in Asia and Africa.

Super Religare Laboraties - part of Fortis Group was floated in 1995 by Parvinder Singh. Fortis Healthcare owns 71.5% of the equity share capital in Super Religare.

It was incorporated as a 'Specialty- Ranbaxy Pvt Ltd', a JV between Specialty Laboratories Asia Ltd and Ranbaxy Laboratories Ltd. The company became public limited company and due to termination of JV agreement, the company's name was changed to 'SRL Ranbaxy Limited'. After the sale of 'Ranbaxy' brand by promoters Malvinder Mohan Singh and Shivinder Mohan Singh, company's name was changed to its present name.

SRL provides diagnostic testing services (routine, specialized and esoteric tests), preventive care testing services and clinical research trial testing services.

It has a network of eight reference laboratories, seven Centres of Excellence, 181 network laboratories, 15 wellness centres and 888 collection centres. Last year, it acquired Piramal Dignostic Services Pvt Ltd (PDPSL) for around R600 Cr.

Super Religare raised R100Cr from Avigo Capital Partners by selling 9.27% stake in a pre-IPO deal. It was followed by a R50Cr equity infusion by Sabre Capital in May'11. The company filed for an IPO in February'11 but withdrew it later due to adverse market scenario. It had planned a public issue of 28 Mn shares including pre-IPO placement of Rs.160 Cr of 8 Mn equity shares.

It was incorporated as a 'Specialty- Ranbaxy Pvt Ltd', a JV between Specialty Laboratories Asia Ltd and Ranbaxy Laboratories Ltd. The company became public limited company and due to termination of JV agreement, the company's name was changed to 'SRL Ranbaxy Limited'. After the sale of 'Ranbaxy' brand by promoters Malvinder Mohan Singh and Shivinder Mohan Singh, company's name was changed to its present name.

SRL provides diagnostic testing services (routine, specialized and esoteric tests), preventive care testing services and clinical research trial testing services.

It has a network of eight reference laboratories, seven Centres of Excellence, 181 network laboratories, 15 wellness centres and 888 collection centres. Last year, it acquired Piramal Dignostic Services Pvt Ltd (PDPSL) for around R600 Cr.

Super Religare raised R100Cr from Avigo Capital Partners by selling 9.27% stake in a pre-IPO deal. It was followed by a R50Cr equity infusion by Sabre Capital in May'11. The company filed for an IPO in February'11 but withdrew it later due to adverse market scenario. It had planned a public issue of 28 Mn shares including pre-IPO placement of Rs.160 Cr of 8 Mn equity shares.

Previous Article

Update: UTI Capital Invests R100Cr In IOT Infra

Next Article

Bain, TPG, Sanjeev To Exit Lilliput Kidswear